Tempest Reveals Emerging Data From TPST-2003 Redeem-1 Study
TPST-2003 delivered a 100% complete response rate among the six efficacy-evaluable patients in the ongoing REDEEM-1 Phase 1/2a trial,...
Jon Napitupulu
Crescent BioPharma Doses First Patient in CR-001 Tumor Trial
Crescent Biopharma has dosed the first patient in ASCEND (NCT07335497), a global, open-label Phase 1/2 trial of CR-001, a...
Starton Doses First Patient in Phase 2a Myeloma Study
In a small Phase 1b study of six relapsed/refractory multiple myeloma patients, continuous low‑dose lenalidomide (STAR-LLD) produced one complete...
Klothea Bio Launches mRNA Trial for Lifespan Extension
Klothea Bio has initiated a randomized, double-blind, placebo-controlled Phase 1b study of AKL003, an intravenous alpha Klotho mRNA therapeutic...
PDS Biotech Amends Phase 3 Trial for Accelerated Approval
PDS Biotechnology has amended its Phase 3 VERSATILE-003 trial to add progression-free survival as an interim primary endpoint to...
FDA Approves Phase 2 Trial for Daré’s Promising HPV Drug
FDA has cleared Daré Bioscience’s IND for DARE-HPV, a fixed-dose lopinavir/ritonavir vaginal insert, enabling a Phase 2 study in...
Cyclerion Advances CYC-126 Phase 2 Study With FDA Feedback
Cyclerion received positive written FDA feedback on its planned Phase 2 proof‑of‑concept study of CYC‑126 in treatment‑resistant depression, with...
Ocular Therapeutix to Announce SOL-1 Wet AMD Trial Data
Ocular Therapeutix will disclose topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related...
InnoCare Doses First Patient in Urticaria Trial in China
InnoCare Pharma has dosed the first patient in a seamless Phase II/III trial of its oral TYK2 inhibitor soficitinib...
Lyell Launches First Head-to-Head CAR T-Cell Lymphoma Trial
Updated data presented at ASH 2025 set the clinical bar Lyell now intends to clear in registration: in third-line-plus...